Harvard Medical School And Cellectricon Collaborate Around Whole-Genome RNAi Screening Technology - Cellaxess(R)HT

Main Category: Genetics
Also Included In: Medical Devices / Diagnostics;  Biology / Biochemistry;  Pharma Industry / Biotech Industry
Article Date: 25 Nov 2008 - 3:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Cellectricon, a leading provider of automated screening solutions for drug discovery, today announced its collaboration with Harvard Medical School, the ICCB-Longwood Screening Facility ("ICCB-L"). Harvard Medical School (ICCB-L) will utilize the Cellaxess(R)HT system, the world's first system for high throughput transfection enabling reagent-free delivery of genetic material to a wide range of biologically relevant cell types.

"We are excited about the collaboration with Cellectricon and the opportunity we have to evaluate Cellaxess(R)HT for genome-wide RNAi delivery to biologically relevant cell types," says Caroline Shamu, Director of ICCB-L.

"Cellectricon is extremely proud to collaborate with a world-class research institution such as Harvard Medical School (ICCB-L)," says Jonas Ohlsson, CEO at Cellectricon. "We look forward to jointly advance the RNAi research area by our technology, as we're confident that Cellaxess(R)HT will aid in the generation of more relevant results from RNAi screening campaigns."

About Cellectricon

Cellectricon AB, a Swedish biotech company, successfully provides groundbreaking products to the pharmaceutical and biotechnology industries. The company utilizes state-of-the-art interfaces to biological systems by employing novel microfluidic technologies. This enables completely new types of assays and devices with superior performance characteristics and robustness. Cellectricon's products address critical bottlenecks in the drug discovery process and have been adopted by top-reference customers, including nine of the top ten pharmaceutical companies. In 2007, the company increased its annual revenue by almost 50%. In 2008-2009 the company is launching two pioneering large-scale screening platforms developed in close collaboration with leaders in the pharmaceutical industry. Used in pre-clinical pharmaceutical development, the Cellaxess(R)HT System enables high throughput RNAi screening and the Dynaflow(R)HT System greatly advances ion channel drug discovery.

Cellectricon AB